2 weeks Ago By ABMN Staff
Federated Hermes Inc. lowered its holdings in shares of RxSight, Inc. ( NASDAQ:RXST – Free Report ) by 91.
1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,146 shares of the company’s stock after selling 63,118 shares during the quarter. Federated Hermes Inc.
’s holdings in RxSight were worth $211,000 as of its most recent SEC filing. Several other hedge funds also recently bought and sold shares of the business. Wells Fargo & Company MN lifted its position in shares of RxSight by 1.
7% during the fourth quarter. Wells Fargo & Company MN now owns 26,574 shares of the company’s stock worth $914,000 after purchasing an additional 445 shares during the last quarter. LPL Financial LLC increased its stake in RxSight by 3.
6% in the 4th quarter. LPL Financial LLC now owns 25,007 shares of the company’s stock worth $860,000 after buying an additional 861 shares during the period. KBC Group NV lifted its holdings in RxSight by 71.
0% during the 4th quarter. KBC Group NV now owns 2,107 shares of the company’s stock valued at $72,000 after buying an additional 875 shares in the last quarter. Hanover Advisors Inc.
boosted its position in RxSight by 18.2% in the 4th quarter. Hanover Advisors Inc.
now owns 6,498 shares of the company’s stock valued at $223,000 after buying an additional 1,000 shares during the period. Finally, Private Trust Co. NA bought a new position in RxSight in the 4th quarter worth about $34,000.
Institutional investors own 78.78% of the company’s stock. Insider Buying and Selling at RxSight In other RxSight news, Director Tamara Fountain sold 7,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th.
The shares were sold at an average price of $25.71, for a total transaction of $179,970.00.
Following the completion of the transaction, the director now directly owns 24,793 shares of the company’s stock, valued at approximately $637,428.03. This trade represents a 22.
02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link . Also, Director Shweta Maniar sold 3,519 shares of the company’s stock in a transaction on Wednesday, January 22nd.
The shares were sold at an average price of $30.87, for a total transaction of $108,631.53.
Following the completion of the sale, the director now directly owns 7,383 shares in the company, valued at $227,913.21. This trade represents a 32.
28 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Company insiders own 9.
36% of the company’s stock. RxSight Stock Down 0.6 % RxSight ( NASDAQ:RXST – Get Free Report ) last posted its quarterly earnings data on Tuesday, February 25th.
The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.10 by ($0.
25). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.
92%. The company had revenue of $40.21 million for the quarter, compared to analyst estimates of $40.
23 million. As a group, research analysts anticipate that RxSight, Inc. will post -0.
7 earnings per share for the current fiscal year. Wall Street Analyst Weigh In RXST has been the subject of several recent research reports. UBS Group downgraded RxSight from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $45.
00 to $16.00 in a report on Wednesday, April 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $43.
00 price target on shares of RxSight in a research report on Thursday, April 3rd. Wells Fargo & Company dropped their price objective on shares of RxSight from $35.00 to $22.
00 and set an “equal weight” rating on the stock in a research note on Thursday, April 3rd. Piper Sandler began coverage on shares of RxSight in a research note on Tuesday. They issued a “neutral” rating and a $18.
00 price objective for the company. Finally, Stifel Nicolaus dropped their target price on RxSight from $33.00 to $28.
00 and set a “hold” rating on the stock in a research report on Wednesday, March 19th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, RxSight has an average rating of “Hold” and a consensus price target of $37.
60. Check Out Our Latest Research Report on RXST RxSight Profile ( Free Report ) RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Featured Stories Want to see what other hedge funds are holding RXST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RxSight, Inc. ( NASDAQ:RXST – Free Report ).
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter ..
